Skip to content

Where AI Should Actually Earn Its Keep in Biopharma - with Mukhtar Ahmed of Greenstone Biosciences

September 29, 2026 · 22 min

Show notes

In biopharma R&D, AI investment has overwhelmingly targeted generating more drug candidates, even though the industry has rarely lacked for compounds worth pursuing. In this episode, Mukhtar Ahmed, Director of Project and Portfolio Strategy at Greenstone Biosciences, explores why the harder and more valuable problem is deciding which candidates deserve continued capital and attention. The conversation covers synthesizing fragmented evidence across teams, keeping human judgment and accountability in the loop, and measuring AI's impact across a portfolio rather than a single program. ​ Emerj works with a select group of AI vendors to reach Fortune 500 decision-makers through research, media, and direct access. If you want to be considered, download our media kit at emerj.com/AD1

All episodes of The AI in Business Podcast

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.